Skip to content

Study · Observational study · n = 139 · 2000

10 results

Growth hormone treatment of short children born small for gestational age: growth responses with continuous and discontinuous regimens over 6 years.

de Zegher F, Albertsson-Wikland K, Wollmann HA, Chatelain P, Chaussain JL, Löfström A, Jonsson B, Rosenfeld RG

The Journal of clinical endocrinology and metabolism1 Aug 2000Cited by 91 (Europe PMC)

PMID10946888 (opens in a new tab)DOI10.1210/jcem.85.8.6719 (opens in a new tab)PepBankPUB-10946888
Source linkPubMedAsk about this study
Jump to 10 results

Summary

The text of this summary is not shown here, because the article license does not allow reuse. Read it at the source (opens in a new tab)

Text rights: Publisher copyright. Results still quote short attributed sentences.

Results from this study10

10 results from studies that gave the peptide. 10 results from people.

  1. 01HumanObservational studyEfficacy outcome

    In short children born small for gestational age, puberty began in 46% of the GH-treated cohort.

    In plain wordsIn short children born small for gestational age, puberty began in 46% of the GH-treated cohort.

    Peptide
    HGH (somatotropin)
    Outcome
    Not applicablePuberty onset proportion
    Study

    n = 139

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Proportion of GH-treated cohort with puberty onset
    46%
    GH-treated children born SGA

    Source sentences

    Summary
    Onset of puberty was observed in 46% of the GH-treated cohort, on the average, at 10.7 yr in girls and 11.7 yr in boys.
    1 context sentence
    Summary · context
    A total of 49 untreated and 139 treated children were followed over 2 and 6 yr, respectively.
  2. 02HumanObservational studyEfficacy outcome

    In GH-treated short children born small for gestational age, bone maturation progressed similarly across treatment subgroups.

    In plain wordsIn GH-treated short children born small for gestational age, bone maturation progressed similarly across treatment subgroups.

    Peptide
    HGH (somatotropin)
    Outcome
    No significant changeBone maturation across treatment subgroups
    Study

    n = 139

    Comparator
    Other GH treatment subgroups
    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Bone maturation progressed similarly in all treatment subgroups, and after 6 yr of study, bone age remained slightly delayed compared to chronological age.
    1 context sentence
    Summary · context
    A total of 49 untreated and 139 treated children were followed over 2 and 6 yr, respectively.
  3. 03HumanObservational studyEfficacy outcome

    In GH-treated short children born small for gestational age, bone age remained slightly delayed relative to chronological age after 6 years.

    In plain wordsIn GH-treated short children born small for gestational age, bone age remained slightly delayed relative to chronological age after 6 years.

    Peptide
    HGH (somatotropin)
    Outcome
    Not applicableBone age relative to chronological age
    Study

    n = 139

    Outcome group
    Bone and joint · Musculoskeletal
    Studied dose
    Dose not stated · 6 yearsAs given in this study (human).

    Source sentences

    Summary
    Bone maturation progressed similarly in all treatment subgroups, and after 6 yr of study, bone age remained slightly delayed compared to chronological age.
  4. 04HumanObservational studySafety outcome

    In short children born small for gestational age, GH treatment was well tolerated.

    In plain wordsIn short children born small for gestational age, GH treatment was well tolerated.

    Peptide
    HGH (somatotropin)
    Outcome
    Not applicableTreatment tolerability
    Study

    n = 139

    Outcome group
    Adverse events · Whole body
    Studied dose
    Dose not stated

    Source sentences

    Summary
    GH treatment was well tolerated.
    1 context sentence
    Summary · context
    A total of 49 untreated and 139 treated children were followed over 2 and 6 yr, respectively.
  5. 05HumanObservational studyEfficacy outcome

    In short children born small for gestational age, continuous GH at 33 microg/kg per day produced a height increment of 2.0 +/- 0.2 SD over 6 years.

    In plain wordsIn short children born small for gestational age, height increased by 2.0 +/- 0.2 SD during continuous GH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseHeight increment at 33 microg/kg per day
    Study

    n = 35

    Outcome group
    Linear growth · Musculoskeletal
    Studied dose
    33 microg/kg x day · 6 yearsAs given in this study (human).

    Measurements

    Height increment over 6 years
    2 SD score
    continuous GH 33 microg/kg x day, n = 35; +/- 0.2 SD

    Source sentences

    Summary
    Continuous GH treatment for 6 yr resulted in height increments of 2.0 +/- 0.2 SD (33 microg/kg x day; n = 35) and 2.7 +/- 0.2 SD (67 microg/kg x day; n = 27).
  6. 06HumanObservational studyEfficacy outcome

    In short children born small for gestational age, continuous GH at 67 microg/kg per day produced a height increment of 2.7 +/- 0.2 SD over 6 years.

    In plain wordsIn short children born small for gestational age, height increased by 2.7 +/- 0.2 SD during continuous GH treatment.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseHeight increment at 67 microg/kg per day
    Study

    n = 27

    Outcome group
    Linear growth · Musculoskeletal
    Studied dose
    67 microg/kg x day · 6 yearsAs given in this study (human).

    Measurements

    Height increment over 6 years
    2.7 SD score
    continuous GH 67 microg/kg x day, n = 27; +/- 0.2 SD

    Source sentences

    Summary
    Continuous GH treatment for 6 yr resulted in height increments of 2.0 +/- 0.2 SD (33 microg/kg x day; n = 35) and 2.7 +/- 0.2 SD (67 microg/kg x day; n = 27).
  7. 07HumanObservational studyEfficacy outcome

    In GH-treated short girls born small for gestational age, puberty began at an average age of 10.7 years.

    In plain wordsIn GH-treated short girls born small for gestational age, puberty began at an average age of 10.7 years.

    Peptide
    HGH (somatotropin)
    Outcome
    Not applicablePuberty onset age in girls
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Average age at puberty onset
    10.7 years
    girls, among those who entered puberty (46% of GH-treated cohort)

    Source sentences

    Summary
    Onset of puberty was observed in 46% of the GH-treated cohort, on the average, at 10.7 yr in girls and 11.7 yr in boys.
  8. 08HumanObservational studyEfficacy outcome

    In GH-treated short boys born small for gestational age, puberty began at an average age of 11.7 years.

    In plain wordsIn GH-treated short boys born small for gestational age, puberty began at an average age of 11.7 years.

    Peptide
    HGH (somatotropin)
    Outcome
    Not applicablePuberty onset age in boys
    Study

    n: not reported in source

    Outcome group
    Sex hormones and fertility · Reproductive and sexual health
    Studied dose
    Dose not stated

    Measurements

    Average age at puberty onset
    11.7 years
    boys, among those who entered puberty (46% of GH-treated cohort)

    Source sentences

    Summary
    Onset of puberty was observed in 46% of the GH-treated cohort, on the average, at 10.7 yr in girls and 11.7 yr in boys.
  9. 09HumanObservational studyEfficacy outcome

    In short children born small for gestational age treated with GH, mean parental-adjusted height SDS had increased to -0.4 +/- 0.1 after 2 years and stabilized thereafter.

    In plain wordsIn short children born small for gestational age, the adjusted height score had risen to -0.4 after 2 years of GH and then stayed stable.

    Peptide
    HGH (somatotropin)
    Outcome
    IncreaseParental-adjusted height SDS after 2 years
    Study

    n: not reported in source

    Outcome group
    Linear growth · Musculoskeletal
    Studied dose
    Dose not stated

    Measurements

    Mean adjusted height SD score after 2 years
    −0.4 SD score
    GH-treated children; +/- 0.1

    Source sentences

    Summary
    After 2 yr, the mean adjusted height SD score had increased to -0.4 +/- 0.1 and stabilized thereafter.
    1 context sentence
    Summary · context
    A total of 49 untreated and 139 treated children were followed over 2 and 6 yr, respectively.
  10. 10HumanObservational studyOther

    In GH-treated short children born small for gestational age, average GH dose, parental-adjusted height SDS, and starting age predicted growth response.

    In plain wordsIn GH-treated short children born small for gestational age, average GH dose, parental-adjusted height SDS, and starting age predicted growth response.

    Peptide
    HGH (somatotropin)
    Outcome
    Direction not reportedPredictors of growth response
    Study

    n: not reported in source

    Outcome group
    Linear growth · Musculoskeletal
    Studied dose
    Dose not stated

    Source sentences

    Summary
    Multivariate analysis identified the average GH dose over 6 yr, parental-adjusted height SD score, and age at start as prime predictors of the growth response.

AI wrote and checked these results. AI can make mistakes, so check important results against the source.

Version history

PepBank keeps every version of the data on this study. Status changes from Retraction Watch, Europe PMC and Crossref are listed with their source.

  1. Version 2Current

    28 Oct 2026, 02:03 UTC

    Study results updated

  2. Version 1

    27 Oct 2026, 16:36 UTC

    First added · source update from Europe PMC

Subjects

Terms as the source lists them.

PepBank is a research reference. Talk to a doctor before you use any peptide.